Home » Mt. Sinai, Berg Ink Omics Deal Directed at Cancer, CNS, Endocrine Disorders

Mt. Sinai, Berg Ink Omics Deal Directed at Cancer, CNS, Endocrine Disorders

Oct 10, 2013
|
staff reporter

NEW YORK (GenomeWeb News) – The Icahn School of Medicine at Mt. Sinai and biopharmaceutical firm Berg today announced a five-year partnership aimed at cancer, as well as central nervous system and endocrine disorders.

The agreement will take a multi-omics and big data analytical approach to gain insight into the three disease areas in order to potentially develop therapeutics and diagnostic tools, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

What's Popular?

In Diagnostics

  1. Ambry Genetics, FDNA Ink Deal to Integrate Technologies

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.